Novavax Shares Fall After RFK Jr. Questions Covid-19 Vaccine

MT Newswires Live04-11

Novavax (NVAX) shares were down sharply Thursday after US Health and Human Services Secretary Robert Kennedy Jr., raised doubts about the effectiveness of the company's Covid-19 vaccine.

Novavax's Nuvaxovid Covid-19 vaccine is currently available under conditional approval and is awaiting full approval from the US Food and Drug Administration, which was expected by April 1, Bloomberg reported.

In a CBS News interview on Wednesday, Kennedy attributed the delay to the vaccine's single-antigen composition, saying such vaccines have "never worked" for respiratory diseases.

"We are actually shifting our priorities to multiple antigen vaccines. And [National Institutes of Health] is already working on a number of those," Kennedy said.

Shares of other Covid-19 vaccine manufacturers including Moderna (MRNA), BioNTech (BNTX), Inovio Pharmaceuticals (INO) and Pfizer (PFE) were also falling after Kennedy's comments.

Novavax didn't immediately respond to a request for comment from MT Newswires.

Price: 5.19, Change: -1.56, Percent Change: -23.05

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2526513593?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-11 00:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2526513593","market":"sg","top_or_hot":-1,"title":"Novavax Shares Fall After RFK Jr. Questions Covid-19 Vaccine","media":"MT Newswires Live","content":"<html><body><p> Novavax (NVAX) shares were down sharply Thursday after US Health and Human Services Secretary Robert Kennedy Jr., raised doubts about the effectiveness of the company's Covid-19 vaccine.</p><p>Novavax's Nuvaxovid Covid-19 vaccine is currently available under conditional approval and is awaiting full approval from the US Food and Drug Administration, which was expected by April 1, Bloomberg reported.</p><p>In a CBS News interview on Wednesday, Kennedy attributed the delay to the vaccine's single-antigen composition, saying such vaccines have \"never worked\" for respiratory diseases.</p><p>\"We are actually shifting our priorities to multiple antigen vaccines. And [National Institutes of Health] is already working on a number of those,\" Kennedy said.</p><p>Shares of other Covid-19 vaccine manufacturers including Moderna (MRNA), BioNTech (BNTX), Inovio Pharmaceuticals (INO) and Pfizer (PFE) were also falling after Kennedy's comments.</p><p>Novavax didn't immediately respond to a request for comment from MT Newswires.</p><p>Price: 5.19, Change: -1.56, Percent Change: -23.05</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Shares Fall After RFK Jr. Questions Covid-19 Vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Shares Fall After RFK Jr. Questions Covid-19 Vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-04-11 00:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Novavax (NVAX) shares were down sharply Thursday after US Health and Human Services Secretary Robert Kennedy Jr., raised doubts about the effectiveness of the company's Covid-19 vaccine.</p><p>Novavax's Nuvaxovid Covid-19 vaccine is currently available under conditional approval and is awaiting full approval from the US Food and Drug Administration, which was expected by April 1, Bloomberg reported.</p><p>In a CBS News interview on Wednesday, Kennedy attributed the delay to the vaccine's single-antigen composition, saying such vaccines have \"never worked\" for respiratory diseases.</p><p>\"We are actually shifting our priorities to multiple antigen vaccines. And [National Institutes of Health] is already working on a number of those,\" Kennedy said.</p><p>Shares of other Covid-19 vaccine manufacturers including Moderna (MRNA), BioNTech (BNTX), Inovio Pharmaceuticals (INO) and Pfizer (PFE) were also falling after Kennedy's comments.</p><p>Novavax didn't immediately respond to a request for comment from MT Newswires.</p><p>Price: 5.19, Change: -1.56, Percent Change: -23.05</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4532","symbol_name":"文艺复兴科技持仓","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2526513593","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2526513593","pubTimestamp":1744301104,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Novavax  shares were down sharply Thursday after US Health and Human Services Secretary Robert Kennedy Jr., raised doubts about the effectiveness of the company's Covid-19 vaccine.Novavax's Nuvaxovid Covid-19 vaccine is currently available under conditional approval and is awaiting full approval from the US Food and Drug Administration, which was expected by April 1, Bloomberg reported.In a CBS News interview on Wednesday, Kennedy attributed the delay to the vaccine's single-antigen composition, saying such vaccines have \"never worked\" for respiratory diseases.\"We are actually shifting our priorities to multiple antigen vaccines. And [National Institutes of Health] is already working on a number of those,\" Kennedy said.Shares of other Covid-19 vaccine manufacturers including Moderna , BioNTech , Inovio Pharmaceuticals  and Pfizer  were also falling after Kennedy's comments.Novavax didn't immediately respond to a request for comment from MT Newswires.Price: 5.19, Change: -1.56, Percent ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4532":"文艺复兴科技持仓","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4007":"制药","BK4501":"段永平概念","BK4599":"减肥药","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","INO":"伊诺维奥制药","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","PFE.AU":"PANTERA MINERALS LTD","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","BK4581":"高盛持仓","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0234572021.USD":"高盛美国核心股票组合Acc","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","BK4535":"淡马锡持仓","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","BK4139":"生物科技","LU0058720904.USD":"联博国际健康护理基金A","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","BK4588":"碎股","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4583":"猴痘概念","BK4550":"红杉资本持仓","NVAX":"诺瓦瓦克斯医药","BK7095":"多种金属与采矿","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","BNTX":"BioNTech SE","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","MRNA":"Moderna, Inc.","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","BK4551":"寇图资本持仓","BK4568":"美国抗疫概念","BK4592":"伊斯兰概念","BK4534":"瑞士信贷持仓","SG9999002232.USD":"Allianz Global High Payout USD","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF"},"translate_title":"RFK Jr.质疑Covid-19疫苗后Novavax股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE.AU":1,"BNTX":1,"INO":0.9,"MRNA":0.9,"NVAX":1},"content_text":"Novavax (NVAX) shares were down sharply Thursday after US Health and Human Services Secretary Robert Kennedy Jr., raised doubts about the effectiveness of the company's Covid-19 vaccine.Novavax's Nuvaxovid Covid-19 vaccine is currently available under conditional approval and is awaiting full approval from the US Food and Drug Administration, which was expected by April 1, Bloomberg reported.In a CBS News interview on Wednesday, Kennedy attributed the delay to the vaccine's single-antigen composition, saying such vaccines have \"never worked\" for respiratory diseases.\"We are actually shifting our priorities to multiple antigen vaccines. And [National Institutes of Health] is already working on a number of those,\" Kennedy said.Shares of other Covid-19 vaccine manufacturers including Moderna (MRNA), BioNTech (BNTX), Inovio Pharmaceuticals (INO) and Pfizer (PFE) were also falling after Kennedy's comments.Novavax didn't immediately respond to a request for comment from MT Newswires.Price: 5.19, Change: -1.56, Percent Change: -23.05","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2526513593","isCrawlerRequest":true}